Newly discovered proteins associated with cystic fibrosis

November 03, 2006

FORT LAUDERDALE, FL (Nov. 3, 2006) _ Researchers have found a highly unusual distribution of two proteins in the lungs and airways of people with cystic fibrosis, a discovery that could be a step in determining how the disease progresses. The proteins, first uncovered as a result of the human genome project, are thought to play a role in the body's immune system.

The discovery is preliminary, but intriguing: Finding out more about the proteins could help sort out the immune system's role in cystic fibrosis, a genetic disease that attacks the lungs and other organs and dramatically shortens life expectancy.

The study "Comparative expression of SPLUNC1, SPLUNC2 and LPLUNC1 in normal and diseased lungs," was carried out by Lynne Bingle of the University of Sheffield School of Clinical Dentistry, Sheffield, United Kingdom, and Colin Bingle, University of Sheffield Medical School, Sheffield. They will present the study at a meeting of The American Physiological Society, "Physiological Genomics and Proteomics of Lung Disease," on Nov. 3. The meeting takes place Nov. 2-5 in Fort Lauderdale.

"Our results show unique expression domains for (the proteins) within the airways and suggest that alterations in expression of these putative innate immune molecules may be associated with lung disease," the authors wrote.

Recently discovered proteins

"We've shown these proteins to be expressed in places like the upper airways, nose and mouth, where many bacteria and infectious agents are found," Bingle said. These tiny molecules are thought to be part of the first line of the body's defenses against infectious agents, Bingle said.

The human genome project localized the PLUNC (palate, lung and nasal epithelium clone) gene to chromosome 20. A genetic locus in this region directs the production of a family of at least 10 proteins. Some of the proteins are short, referred to as "SPLUNCs," while others are long, referred to as "LPLUNCs."

Researchers have found that these proteins locate in specific places in the bodies of healthy people. Because these proteins are found in different areas, researchers speculate that they may have slightly different functions and may fight different infectious agents.

Investigation with cystic fibrosis

People with cystic fibrosis have a faulty gene, which normally controls the movement of salt into and out of cells and this controls the movement of water, too, Bingle explained. In a patient with cystic fibrosis, there is too little salt and water on the outside of cells lining the airways. This means that the normally thin protective layer of mucus becomes thick and very difficult to move.

It is very difficult for the patient to cough up the thick mucus, so the airways get clogged. The trapped mucous becomes a haven for infectious agents, which leads to long-term infection, inflammation and scarring. Most patients will eventually need lung transplants in order to survive, she said.

In this study, the researchers compared the tissue of 21 cystic fibrosis patients -- all of whom had end stage disease and were scheduled for a transplant -- to healthy tissue. The healthy tissue was obtained from 10 patients undergoing surgical removal of a lung tumor. The researchers used the healthy portion of lung tissue which is usually excised along with the tumor.

The study looked at tissue samples from the lung's upper airway, just below the trachea, and from lower down in the airway, in the peripheral lung, where gas exchange takes place.

This lower region of the lung has small airways as well as the gas-exchange tissue. They used a staining technique to find SPLUNC1, SPLUNC2 and LPLUNC1.

In normal lungs: The study found that the presence of SPLUNC1 is "massively increased in the small airways of the lungs of people with cystic fibrosis," Bingle said. "It is really difficult to find SPLUNC 1 in similar airways from the normal lung."

LPLUNC1 also increases significantly in the small airways of people with cystic fibrosis compared to normal tissue, Bingle noted. It is normal to have LPLUNC1 in this region, but people with cystic fibrosis have a much greater amount of it here.

The study found no differences in SPLUNC2 between the diseased and normal lungs. SPLUNC2 appears to be exclusively expressed in the mouth.

A step in the fight against cystic fibrosis

These findings could become a way to prevent cystic fibrosis related lung damage, most of which occurs because of the constant infections these people suffer, Bingle said. The body's immune reaction to the infection also damages the lungs, "so knowing how these immune reactions happen could help doctors prevent them or harness them to fight the infection before it becomes established," she said.
-end-
The media can attend this fascinating conference, or request an interview with Dr. Bingle, by contacting Christine Guilfoy, at cguilfoy@the-aps.org or at (301) 634-7253. For reporters who cannot attend, arrangements can be made in many cases for telephone interviews with scientists. Please go to http://www.the-aps.org/meetings/aps/ftlauderdale/index.htm for more about the program.

The American Physiological Society was founded in 1887 to foster basic and applied bioscience. The Bethesda, Maryland-based society has 10,500 members and publishes 14 peer-reviewed journals containing almost 4,000 articles annually.

APS provides a wide range of research, educational and career support and programming to further the contributions of physiology to understanding the mechanisms of diseased and healthy states. In 2004, APS received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring.

American Physiological Society

Related Cystic Fibrosis Articles from Brightsurf:

Treating cystic fibrosis with mRNA therapy or CRISPR
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.

New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.

Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.

In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read More: Cystic Fibrosis News and Cystic Fibrosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.